Politerapi Kullanan Epilepsi Hastalarının Monoterapi Kullanan Hastalardan Farklılıkları

Özgür Topçuoğlu; Kadriye Ağan; İpek Midi; Canan Aykut Bingöl

-

Yıl 2012, Cilt: 25 Sayı: 3, 123 - 127, 18.03.2015

Özgür Topçuoğlu Kadriye Ağan İpek Midi Canan Aykut Bingöl

Öz

Anahtar Kelimeler

Kaynakça

1. Hopkins A, Shorvon S. Definitions and epidemiology of epilepsy. In: Hopkins A, Shorvon S, Cascino G, eds. Epilepsy. 2nd ed. London: Chapman and Hall Medical, 1995: 1-11.
2. Holden EW, Thanh Nguyen H, Grossman E, et al. Estimating prevalence, incidence, and disease-related mortality for patients with epilepsy in managed care organizations. Epilepsia 2005; 46: 311-9. doi:10.1111/j.0013-9580.2005.30604.x
3. Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or addon? Seizure 2000; 9: 464-8. doi:10.1053/seiz.2000.0442
4. St Louis EK. Monotherapy to polytherapy: antiepileptic drug conversions through the spectrum of epilepsy care. Curr Neuropharmacol 2009; 7: 75-6. doi:10.2174/157015909788848910
5. St Louis EK. Truly “rational” polytherapy: maximizing efficacy and minimizing drug interactions, drug loads , and adverse effects. Curr Neuropharmacol 2009; 7: 96-105. doi:10.2174/157015909788848929
6. French JA, Faught E. Rational polytherapy. Epilepsia 2009;50:63-8. doi:10.1111/j.1528-1167.2009.02238.x
7. Garnett WR, St.Louis EK, Henry TR, Bramley T.Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions. Curr Neuropharmacol 2009; 7: 83-95. doi:10.2174/157015909788848884
8. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-9. doi:10.1056/NEJM200002033420503
9. Blumer D, Adamolekun B. Treatment of paitents with coexisting epileptic and nonepileptic seizures. Epilepsy Behav 2006; 9: 498- 502. doi:10.1016/j.yebeh.2006.07.001
10. Schmidt D, Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005; 46: 858-77. doi:10.1111/j.1528-1167.2005.54904.x
11. Volman V, Bazhenov M, Sejnowski TJ. Pattern of trauma determines the treshold for epileptic activity in a model for cortical differentiation. Proc Natl Acad Sci USA 2011; 108: 15402-7. doi:10.1073/pnas.1112066108
12. Alonso-Cerezo C, Herrera- Peco I, Fernandez- Millares V, et al. Family history of epilepsy resistant to treatment. Rev Neurol 2011; 52: 522-6. Abstract.
13. Theodore WH, Bhatia S, Hatta J, et al. Hippocampal atrophy, epilepsy duration, and febrile seizures in patients with partial seizures. Neurology 1999; 52: 132-6.
14. Hamati-Haddad A, Abou-Khalil B. Epilepsy diagnosis and localization in patients with antecedent childhood febrile convulsions. Neurology 1998; 50: 917-22.
15. French JA, Williamson PD, Thadani VM, et al. Characteristics of medial temporal lobe epilepsy: I. Results of history and physical examination. Ann Neurol 1993; 34:774-80. doi:10.1002/ana.410340604
16. Mathern GW, Adelson PD, Cahan LD, Leite JP. Hippocampal neuron damage in human epilepsy: Meyer’s hypothesis revisited. Prog Brian Res 2002; 135: 237-51. doi:10.1016/S0079-6123(02)35023-4
17. De Reuck JL. Stroke-related epilepsy. Neurol Neurochir Pol 2007;41:144-9. doi:10.1111/j.1468-1331.2007.01829.x
18. Kwan J, Wood E. Antiepileptic drugs for the primary and secondary prevention of seizures after stroke. Cochrane Database Syst Rev 2010; 20: CD005398. doi:10.1002/14651858.CD005398
19. Sobani ZA, Shamim MS, Zafar SY, et al. Cranioplasy after decompressive craniectomy: an institutional audit and analysis of factors related to complications. Surg Neurol Int 2011;2: 123.
20. Sun Y, Vestergaard M, Pedersen CB, Christensen J, Olsen J. Apgar scores and long-term risk of epilepsy. Epidemiology 2006; 17:296-301. doi:10.1097/01.ede.0000208478.47401.b6
21. Maschio M, Dinapoli L. Lecture: profile of risks and benefits of new antiepileptic drugs in brain-tumor related epilepsy. Neurol Sci 2011; 32: 259-62. doi:10.1007/s10072-011-0801-3
22. Vecht CJ, Wilms EB. Seizures in low- and high- grade gliomas: current management and future look. Expert Rev Anticancer Ther 2010; 10: 663- 9. (doi:10.1586/era.10.48)
23. Pati S, Alexopoulos AV. Phramacoresistant epilepsy: from pathogenesis to current and emerging therapies. Cleve Clin J Med 2010; 77: 457-67. doi:10.3949/ccjm.77a.09061
24. Wahab A, Albus K, Gabriel S, Heinemann U. In search of models of pharmacoresistant epilepsy. Epilepsia 2010; 3: 154-9. doi:10.1111/j.1528-1167.2010,02632.x
25. Jayalakshmi S, Sudhakar P, Panigrahi M. Role of single photon emission computed tomography in epilepsy. Int J Mol Imaging 2011; 803920. doi:10.1155/2011/803920
26. Cendes F. Neuroimaging predictors of AED resistance in new-onset epilepsies. Epilepsia 2011; 52: 7-9. doi:10.1111/j.1528-1167.2011.03143.x

Politerapi Kullanan Epilepsi Hastalarının Monoterapi Kullanan Hastalardan Farklılıkları

Yıl 2012, Cilt: 25 Sayı: 3, 123 - 127, 18.03.2015

Özgür Topçuoğlu Kadriye Ağan İpek Midi Canan Aykut Bingöl

Öz

Amaç: Bu çalışmanın amacı politerapi altındaki (birden fazla antiepileptik
kullanan) epilepsi hastalarının demografik, klinik, nörolojik muayene ve
görüntüleme sonuçlarının incelenerek politerapi ihtiyacına eşlik eden
faktörlerin belirlenmesidir.
Hastalar ve Yöntem: Marmara Üniversite Hastanesi Epilepsi polikliniğinde
takipli 785 epileptik hastanın dosyası retrospektif olarak taranıp, hazırlanan
formlar doldurulmuştur. Hastalar monoterapi ya da politerapi kullanmalarına
göre gruplanmıştır. İki grup demografik veriler, klinik özellikler, nörolojik
muayene ve görüntüleme sonuçları açısından Student-t ve ki-kare testleri ile
karşılaştırılmıştır.
Bulgular: Politerapi kullanan hasta grubunda öyküde kraniyotomi, intrakraniyal
tümör, basit parsiyel nöbet ve konvülsif status epileptikus, nörolojik muayenede
patolojik bulgu görülmesi, EEG, kranial görüntüleme (MR/BT) ve SPECT’de patoloji
saptanması monoterapi kullanan hasta grubundan daha yüksek bulunmuştur.
Sonuç: Politerapi epilepsi tedavisinde önemli bir basamaktır. Ancak ilaç-ilaç
etkileşimi olasılığı ve artan ilaç yan etkileri nedeniyle ilk seçenek olarak kabul
edilmemektedir. Politerapi kullanacak hastaların monoterapi ile nöbetleri
kontrol altına alınabilen hastalardan farklılıkların belirlenmesi, politerapi
ihtiyacının tedavinin öncesinde tahmin edilmesi açısından faydalı olacaktır

Anahtar Kelimeler

Epilepsi, Politerapi, Etyoloji

Kaynakça

1. Hopkins A, Shorvon S. Definitions and epidemiology of epilepsy. In: Hopkins A, Shorvon S, Cascino G, eds. Epilepsy. 2nd ed. London: Chapman and Hall Medical, 1995: 1-11.
2. Holden EW, Thanh Nguyen H, Grossman E, et al. Estimating prevalence, incidence, and disease-related mortality for patients with epilepsy in managed care organizations. Epilepsia 2005; 46: 311-9. doi:10.1111/j.0013-9580.2005.30604.x
3. Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or addon? Seizure 2000; 9: 464-8. doi:10.1053/seiz.2000.0442
4. St Louis EK. Monotherapy to polytherapy: antiepileptic drug conversions through the spectrum of epilepsy care. Curr Neuropharmacol 2009; 7: 75-6. doi:10.2174/157015909788848910
5. St Louis EK. Truly “rational” polytherapy: maximizing efficacy and minimizing drug interactions, drug loads , and adverse effects. Curr Neuropharmacol 2009; 7: 96-105. doi:10.2174/157015909788848929
6. French JA, Faught E. Rational polytherapy. Epilepsia 2009;50:63-8. doi:10.1111/j.1528-1167.2009.02238.x
7. Garnett WR, St.Louis EK, Henry TR, Bramley T.Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions. Curr Neuropharmacol 2009; 7: 83-95. doi:10.2174/157015909788848884
8. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-9. doi:10.1056/NEJM200002033420503
9. Blumer D, Adamolekun B. Treatment of paitents with coexisting epileptic and nonepileptic seizures. Epilepsy Behav 2006; 9: 498- 502. doi:10.1016/j.yebeh.2006.07.001
10. Schmidt D, Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005; 46: 858-77. doi:10.1111/j.1528-1167.2005.54904.x
11. Volman V, Bazhenov M, Sejnowski TJ. Pattern of trauma determines the treshold for epileptic activity in a model for cortical differentiation. Proc Natl Acad Sci USA 2011; 108: 15402-7. doi:10.1073/pnas.1112066108
12. Alonso-Cerezo C, Herrera- Peco I, Fernandez- Millares V, et al. Family history of epilepsy resistant to treatment. Rev Neurol 2011; 52: 522-6. Abstract.
13. Theodore WH, Bhatia S, Hatta J, et al. Hippocampal atrophy, epilepsy duration, and febrile seizures in patients with partial seizures. Neurology 1999; 52: 132-6.
14. Hamati-Haddad A, Abou-Khalil B. Epilepsy diagnosis and localization in patients with antecedent childhood febrile convulsions. Neurology 1998; 50: 917-22.
15. French JA, Williamson PD, Thadani VM, et al. Characteristics of medial temporal lobe epilepsy: I. Results of history and physical examination. Ann Neurol 1993; 34:774-80. doi:10.1002/ana.410340604
16. Mathern GW, Adelson PD, Cahan LD, Leite JP. Hippocampal neuron damage in human epilepsy: Meyer’s hypothesis revisited. Prog Brian Res 2002; 135: 237-51. doi:10.1016/S0079-6123(02)35023-4
17. De Reuck JL. Stroke-related epilepsy. Neurol Neurochir Pol 2007;41:144-9. doi:10.1111/j.1468-1331.2007.01829.x
18. Kwan J, Wood E. Antiepileptic drugs for the primary and secondary prevention of seizures after stroke. Cochrane Database Syst Rev 2010; 20: CD005398. doi:10.1002/14651858.CD005398
19. Sobani ZA, Shamim MS, Zafar SY, et al. Cranioplasy after decompressive craniectomy: an institutional audit and analysis of factors related to complications. Surg Neurol Int 2011;2: 123.
20. Sun Y, Vestergaard M, Pedersen CB, Christensen J, Olsen J. Apgar scores and long-term risk of epilepsy. Epidemiology 2006; 17:296-301. doi:10.1097/01.ede.0000208478.47401.b6
21. Maschio M, Dinapoli L. Lecture: profile of risks and benefits of new antiepileptic drugs in brain-tumor related epilepsy. Neurol Sci 2011; 32: 259-62. doi:10.1007/s10072-011-0801-3
22. Vecht CJ, Wilms EB. Seizures in low- and high- grade gliomas: current management and future look. Expert Rev Anticancer Ther 2010; 10: 663- 9. (doi:10.1586/era.10.48)
23. Pati S, Alexopoulos AV. Phramacoresistant epilepsy: from pathogenesis to current and emerging therapies. Cleve Clin J Med 2010; 77: 457-67. doi:10.3949/ccjm.77a.09061
24. Wahab A, Albus K, Gabriel S, Heinemann U. In search of models of pharmacoresistant epilepsy. Epilepsia 2010; 3: 154-9. doi:10.1111/j.1528-1167.2010,02632.x
25. Jayalakshmi S, Sudhakar P, Panigrahi M. Role of single photon emission computed tomography in epilepsy. Int J Mol Imaging 2011; 803920. doi:10.1155/2011/803920
26. Cendes F. Neuroimaging predictors of AED resistance in new-onset epilepsies. Epilepsia 2011; 52: 7-9. doi:10.1111/j.1528-1167.2011.03143.x

Toplam 26 adet kaynakça vardır.

Ayrıntılar

Birincil Dil	Türkçe
Bölüm	Makaleler
Yazarlar	Özgür Topçuoğlu Kadriye Ağan Bu kişi benim İpek Midi Bu kişi benim Canan Aykut Bingöl Bu kişi benim
Yayımlanma Tarihi	18 Mart 2015
Yayımlandığı Sayı	Yıl 2012 Cilt: 25 Sayı: 3

Kaynak Göster

APA	Topçuoğlu, Ö., Ağan, K., Midi, İ., Aykut Bingöl, C. (2015). Politerapi Kullanan Epilepsi Hastalarının Monoterapi Kullanan Hastalardan Farklılıkları. Marmara Medical Journal, 25(3), 123-127.
AMA	Topçuoğlu Ö, Ağan K, Midi İ, Aykut Bingöl C. Politerapi Kullanan Epilepsi Hastalarının Monoterapi Kullanan Hastalardan Farklılıkları. Marmara Med J. Ağustos 2015;25(3):123-127.
Chicago	Topçuoğlu, Özgür, Kadriye Ağan, İpek Midi, ve Canan Aykut Bingöl. “Politerapi Kullanan Epilepsi Hastalarının Monoterapi Kullanan Hastalardan Farklılıkları”. Marmara Medical Journal 25, sy. 3 (Ağustos 2015): 123-27.
EndNote	Topçuoğlu Ö, Ağan K, Midi İ, Aykut Bingöl C (01 Ağustos 2015) Politerapi Kullanan Epilepsi Hastalarının Monoterapi Kullanan Hastalardan Farklılıkları. Marmara Medical Journal 25 3 123–127.
IEEE	Ö. Topçuoğlu, K. Ağan, İ. Midi, ve C. Aykut Bingöl, “Politerapi Kullanan Epilepsi Hastalarının Monoterapi Kullanan Hastalardan Farklılıkları”, Marmara Med J, c. 25, sy. 3, ss. 123–127, 2015.
ISNAD	Topçuoğlu, Özgür vd. “Politerapi Kullanan Epilepsi Hastalarının Monoterapi Kullanan Hastalardan Farklılıkları”. Marmara Medical Journal 25/3 (Ağustos 2015), 123-127.
JAMA	Topçuoğlu Ö, Ağan K, Midi İ, Aykut Bingöl C. Politerapi Kullanan Epilepsi Hastalarının Monoterapi Kullanan Hastalardan Farklılıkları. Marmara Med J. 2015;25:123–127.
MLA	Topçuoğlu, Özgür vd. “Politerapi Kullanan Epilepsi Hastalarının Monoterapi Kullanan Hastalardan Farklılıkları”. Marmara Medical Journal, c. 25, sy. 3, 2015, ss. 123-7.
Vancouver	Topçuoğlu Ö, Ağan K, Midi İ, Aykut Bingöl C. Politerapi Kullanan Epilepsi Hastalarının Monoterapi Kullanan Hastalardan Farklılıkları. Marmara Med J. 2015;25(3):123-7.

Makale Dosyaları

Tam Metin